Fentanyl

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
220pxpx }}
220pxpx }}
Fentanyl
Systematic (IUPAC) name
N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-propanamide
Identifiers
CAS number 437-38-7
ATC code N01AH01 N02AB03
PubChem 3345
DrugBank APRD00347
Chemical data
Formula C22H28N2O 
Mol. mass 336.471 g/mol
Physical data
Melt. point 87.5 °C (190 °F)
Pharmacokinetic data
Bioavailability 92% (transdermal)
50% (buccal)
Protein binding 80-85%
Metabolism hepatic, primarily by CYP3A4
Half life 7 hours (range 3–12 h)
Excretion Urine
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Schedule II(US)

Dependence Liability Moderate - High
Routes TD, IM, IV, oral, sublingual, buccal

WikiDoc Resources for

Fentanyl

Articles

Most recent articles on Fentanyl

Most cited articles on Fentanyl

Review articles on Fentanyl

Articles on Fentanyl in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fentanyl

Images of Fentanyl

Photos of Fentanyl

Podcasts & MP3s on Fentanyl

Videos on Fentanyl

Evidence Based Medicine

Cochrane Collaboration on Fentanyl

Bandolier on Fentanyl

TRIP on Fentanyl

Clinical Trials

Ongoing Trials on Fentanyl at Clinical Trials.gov

Trial results on Fentanyl

Clinical Trials on Fentanyl at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fentanyl

NICE Guidance on Fentanyl

NHS PRODIGY Guidance

FDA on Fentanyl

CDC on Fentanyl

Books

Books on Fentanyl

News

Fentanyl in the news

Be alerted to news on Fentanyl

News trends on Fentanyl

Commentary

Blogs on Fentanyl

Definitions

Definitions of Fentanyl

Patient Resources / Community

Patient resources on Fentanyl

Discussion groups on Fentanyl

Patient Handouts on Fentanyl

Directions to Hospitals Treating Fentanyl

Risk calculators and risk factors for Fentanyl

Healthcare Provider Resources

Symptoms of Fentanyl

Causes & Risk Factors for Fentanyl

Diagnostic studies for Fentanyl

Treatment of Fentanyl

Continuing Medical Education (CME)

CME Programs on Fentanyl

International

Fentanyl en Espanol

Fentanyl en Francais

Businness

Fentanyl in the Marketplace

Patents on Fentanyl

Experimental / Informatics

List of terms related to Fentanyl

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Fentanyl is an opioid analgesic with a potency approximately eighty times that of morphine. Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans, by intravenous injection in an opiate naive individual (without tolerance), is 0.2-1 milligrams. In the United States, fentanyl is a Schedule II drug.

History

Fentanyl was first synthesized by Janssen Pharmaceutica (Belgium) in the late 1950s. Fentanyl was introduced into medical practice in the 1960s as an intravenous anesthetic under the trade name of Sublimaze.

Chemistry

Synthesis

The synthesis of fentanyl (N-phenyl-N-(1-phenethyl-4-piperidinyl)propanamide) by Janssen Pharmaceutica was achieved in four steps, starting from 4-piperidinone hydrochloride. The 4-piperidinone hydrochloride was first reacted with phenethyl bromide to give N-phenethyl-4-piperidinone (NPP). Treatment of the NPP intermediate with aniline followed by reduction with sodium borohydride afforded 4-anilino-N-phenethyl-piperidine (ANPP). finally ANPP and propionic anhydride are reacted to form the amide product.

Analogues

The pharmaceutical industry has developed several analogues of fentanyl:

  • Alfentanil (trade name Alfenta), an ultra-short acting (5–10 minutes) analgesic,
  • Sufentanil (trade name Sufenta), a potent analgesic (5 to 10 times more potent than fentanyl) for use in heart surgery.
  • Remifentanil (trade name Ultiva), currently the shortest acting opioid, has the benefit of rapid offset, even after prolonged infusions.
  • Carfentanil (trade name Wildnil) is an analogue of fentanyl with an analgesic potency 10,000 times that of morphine and is used in veterinary practice to immobilize certain large animals like an elephant.

Therapeutic use

Fentanyls are extensively used for anesthesia and analgesia, most often in the operating room and intensive care unit. Fentanyl transdermal patch (Duragesic) is used in chronic pain management. Fentanyl patches work by releasing fentanyl into body fats, which then slowly release the drug into the blood stream over 72 hours, allowing for long lasting relief from pain. In the past few years, the patches have gone generic and are available for lower costs. Fentanyl patches are manufactured in five patch sizes: 12.5 micrograms/h, 25 µg/h, 50 µg/h, 75 µg/h, and 100 µg/h. Dosage is based on the size of the patch, since the transdermal absorption rate is generally constant at a constant skin temperature. Rate of absorption is dependent on a number of factors. Body temperature, skin type and placement of the patch can have major effects. The different delivery systems used by different makers will also affect individual rates of absorption. The typical patch will take effect under normal circumstances usually within 8-12 hours, thus fentanyl patches are often prescribed with another opiate (such as morphine sulfate) to handle breakthrough-pain.

Fentanyl lozenges (Actiq) are a solid formulation of fentanyl citrate on a stick in the form of a lollipop that dissolves slowly in the mouth for transmucosal absorption. These lozenges are intended for opioid-tolerant individuals and is effective in treating breakthrough cancer pain. It is also useful for breakthrough pain for those suffering bone injuries, severe back pain, neuropathy, arthritis, and some other examples of chronic nonmalignant pain. The unit is a berry-flavored lozenge on a stick which is swabbed on the mucosal surfaces inside the mouth—inside of the cheeks, under and on the tongue and gums—to release the fentanyl quickly into the system. It is most effective when the lozenge is consumed in 15 minutes. The drug is less effective if swallowed, as despite good absorbance from the small intestine there is extensive first pass metabolism, leading to an oral bioavailability of 33%. Fentanyl lozenges are available in six dosages, from 200 to 1600 µg in 200 µg increments (excluding 1000 µg and 1400 µg). These are now available in the United states in generic form,[1] through an FTC consent agreement.[1]
However, most patients find it takes 10-15 minutes to use all of one lozenge, and those with a dry mouth cannot use this route. In addition, nurses are unable to document how much of a lozenge has been used by a patient, making drug records inaccurate. The development of small fentanyl buccal pellets (Fentora) may be much more practical. These are effervescent tablets placed in the cheek and are absorbed through the buccal mucosa. One advantage of such tablets is claimed to be quicker absorption into the bloodstream at lower dosage levels.

Fentanyl is frequently given intrathecally as part of spinal anesthesia or epidurally for epidural anesthesia and analgesia. It is also used as a sedative.

Fentanyl is not considered a first line opioid in palliative care—morphine remains the first line choice, fentanyl is regarded as a second line alternative together with oxycodone and sometimes hydromorphone or methadone.

Adverse effects

Like other lipid soluble drugs, the pharmacodynamics of fentanyl are poorly understood. The manufacturers acknowledge there is no data on the pharmacodynamics of fentanyl in elderly, cachectic or debilitated patients, frequently the type of patient for which transdermal fentanyl is being used. This may explain the increasing number of reports of respiratory depression events since the late 1970s.[1][1][1][1][1][1][1] In 2006 the U.S. Food and Drug Administration started investigating several respiratory deaths.

The precise reason for sudden respiratory depression is unclear, but there are several hypotheses:

  • Saturation of the body fat compartment in patients with rapid and profound body fat loss (patients with cancer, cardiac or infection-induced cachexia can lose 80% of their body fat).
  • Early carbon dioxide retention causing cutaneous vasodilatation (releasing more fentanyl), together with acidosis which reduces protein binding of fentanyl (releasing yet more fentanyl).
  • Reduced sedation, losing a useful early warning sign of opioid toxicity, and resulting in levels closer to respiratory depressant levels.

In palliative care fentanyl has a definite, but limited, role for:

  • Patients already stabilised on other opioids but who cannot swallow
  • Patients with moderate to severe renal failure

Fentanyl has a therapeutic index of 270.[1]

Illicit use

Fentanyl powder seized by a Lake County Deputy Sheriff in Painesville, Ohio, where a male subject had been discovered unresponsive and struggling to breathe
Fentanyl powder seized by a Lake County Deputy Sheriff in Painesville, Ohio, where a male subject had been discovered unresponsive and struggling to breathe

Illicit use of pharmaceutical fentanyls first appeared in the mid-1970s in the medical community and continues in the present. United States authorities classify fentanyl as a narcotic. To date, over 12 different analogues of fentanyl have been produced clandestinely and identified in the U.S. drug traffic. The biological effects of the fentanyls are similar to those of heroin, with the exception that many users report a noticeably less euphoric 'high' associated with the drug and stronger sedative and analgesic effects. Because the effects of fentanyl last for only a very short time, it is even more addictive than heroin, and regular users may become addicted very quickly. Additionally, fentanyl may be hundreds of times more potent than street heroin, and tends to produce significantly worse respiratory depression, making it somewhat more dangerous than heroin to users — though in some places, it is sold as heroin, often leading to overdoses. Fentanyl is most commonly used orally, but like heroin, can also be smoked, snorted or injected. Many fentanyl overdoses were initially classified as heroin overdoses.[1]

Fentanyl is normally sold on the black market in the form of transdermal fentanyl patches such as Duragesic, diverted from legitimate medical supplies. The patches may be cut up and eaten, or the gel from inside the patch smoked. To prevent the removal of the fentanyl base, manufacturers such as Mylan have produced newer forms of fentanyl patches that contain the chemical in a silicon matrix, preventing the removal of the fentanyl-containing gel present in other products.[2] Another dosage form of fentanyl which has appeared on the streets are the fentanyl lollipops Actiq, which are sold under the street name of "percopop". The pharmacy retail price ranges from US$16 to US$50 per unit (based on strength of lozenge), with the black market cost anywhere from US$20 to US$60 per unit, depending on the strength. Non-medical use of fentanyl by individuals without opiate tolerance can be very dangerous and has resulted in numerous deaths.[3] Even those with opiate tolerances are at high risk for overdoses. Once the fentanyl is in the user's system it is extremely difficult to stop its course because of the nature of absorption. Illicitly synthesized fentanyl powder has also appeared on the US market. Because of the extremely high strength of pure fentanyl powder, it is very difficult to dilute appropriately, and often the resulting mixture may be far too strong and consequently very dangerous. Some heroin dealers mix fentanyl powder with larger amounts of heroin in order to increase potency or compensate for low-quality heroin, and to increase the volume of their product. As of December 2006, a mix of fentanyl and either cocaine or heroin has caused an outbreak in overdose deaths in the United States, heavily concentrated in the cities of Detroit, Philadelphia, Pittsburgh, St. Louis, Milwaukee, Camden, Chicago,[1] Little Rock, and Dallas.[1] The mixture of fentanyl and heroin is known as "magic", among other names, on the street.[1]

Several large quantities of illicitly-produced fentanyl have been seized by U.S. law enforcement agencies. In June 2006, 945 grams of 83% pure fentanyl powder were seized by Border Patrol agents in California from a vehicle which had entered from Mexico.[1] Mexico is the source of much of the illicit fentanyl for sale in the U.S. However, there has been one domestic fentanyl lab discovered by law enforcement, in April 2006 in Azusa, California. The lab was a source of counterfeit 80 mg OxyContin tablets containing fentanyl instead of oxycodone, as well as bulk fentanyl and other drugs.[1][1]

The "china white" form of fentanyl refers to the clandestinely produced analogue α-methylfentanyl (AMF).[1] The main bonus of the alpha-methyl is it provides a site of resistance to metabolic degradation resulting in a drug with an increased duration.[1]

References

  • Lehman, K. A., and D. Zech (eds) Transdermal Fentanyl: a new Approach to Prolonged Pain Control, Berlin; New York: Springer-Verlag (1991) ISBN 0387544402

See also

External links


bg:Фентанил cs:Fentanyl de:Fentanylfr:Fentanyl it:Fentanyl hu:Fentanil nl:Fentanyl ja:フェンタニルfi:Fentanyyli sv:Fentanyl th:เฟนทานิล


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools